CD274 and neoplasm: When we considered the cut-off of 1%, instead of 5% of immunoreactive tumor cells, the percentage of PD-L1+ cases increased to 61% for EBV+ and 37% for MSI GCs, whereas it remained unvaried in MSS/EBV− GCs.